| Literature DB >> 32839532 |
Jihye Kim1, Seung Hun Lee2, Tae-Hwan Kim3.
Abstract
Despite the importance of sleep and the evidence on its relationship with various chronic diseases, quality of sleep is not considered in patients with lumbar spinal stenosis (LSS). This prospective comparative study aimed to investigate the changes in sleep disturbance after treatment in patients with LSS. Patients with LSS and sleep disturbance (n = 201; 147 conservatively treated and 54 patients with surgical treatment) were included. The Pittsburgh sleep quality index (PSQI) was used to evaluate sleep quality. Propensity score matching was used to attenuate the potential bias. Clinical outcome of surgery, as determined by the Oswestry disability index, and the PSQI was compared between the two groups at 6 weeks, 3 months, and 6 months after enrollment. Multivariate logistic analysis was performed to adjust for possible confounders within the matched cohorts. Among the 201 patients, 96 (47.7%) patients were finally matched (48 patients in each group). Sleep quality was initially improved after treatment, regardless of the treatment method. Sleep quality in the surgical group was improved by 6 weeks after surgery and consistently improved during the 6-month follow-up period, despite less use of pain killer. Conversely, the improvement in sleep quality at 6-weeks following conservative treatment was not maintained during the follow-up, although the treatment outcome for LSS measured by ODI was continuously improved. After multivariate logistic regression analysis within propensity score matched cohorts, surgical treatment had a significantly greater chance to improve sleep quality compared to conservative treatment. The failure of sleep improvement in conservative group was significantly associated with depression presented by worse score in Hamilton depression rating scale, and more severe degree of foraminal-type stenosis, which should be carefully considered for conservative treatment of LSS patients with sleep disturbance.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32839532 PMCID: PMC7445231 DOI: 10.1038/s41598-020-71145-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Patient enrollment.
Comparison of initial patients’ characteristics.
| Unmatched cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
| Conservative group | Surgical group | p-value | Conservative group | Surgical group | p-value | |
| Number of patients | 147 | 54 | 48 | 48 | ||
| Age | 69.6 ± 10.5 | 71.9 ± 6.7 | 0.067 | 71.4 ± 9.3 | 71.7 ± 7.0 | 0.873 |
| Sex (male:female) | 61:86 (1:1.4) | 17:37 (1:2.2) | 0.197 | 17:31 (1:1.8) | 16:32 (1:2.0) | 0.830 |
| BMI (kg/m2) | 24.4 ± 3.1 | 24.8 ± 3.3 | 0.400 | 24.1 ± 3.2 | 24.9 ± 3.4 | 0.248 |
| Charlson comorbidity index score | 1.4 ± 1.3 | 1.3 ± 1.2 | 0.481 | 1.3 ± 1.3 | 1.3 ± 1.2 | 0.833 |
| Hamilton depression rating scale | 12.7 ± 8.8 | 13.7 ± 8.4 | 0.480 | 13.8 ± 8.4 | 13.5 ± 8.4 | 0.885 |
| Oswestry disability index score | 38.5 ± 17.7 | 41.9 ± 18.4 | 0.234 | 40.1 ± 16.5 | 41.0 ± 17.7 | 0.810 |
| Back pain | 4.9 ± 1.3 | 6.1 ± 1.7 | < 0.001 | 5.5 ± 1.5 | 6.0 ± 1.8 | 0.120 |
| Leg pain | 5.1 ± 1.6 | 6.8 ± 1.8 | < 0.001 | 6.2 ± 1.3 | 6.7 ± 1.9 | 0.094 |
| 0.621 | 0.797 | |||||
| Less than high school | 86 (59) | 28 (52) | 27 (56) | 25 (52) | ||
| High school | 39 (27) | 18 (33) | 13 (27) | 16 (33) | ||
| College and above | 22 (15) | 8 (15) | 8 (17) | 7 (15) | ||
| 0.784 | 0.603 | |||||
| None | 112 (76) | 43 (80) | 40 (83) | 38 (79) | ||
| Sedentary | 25 (17) | 7 (13) | 4 (8) | 7 (15) | ||
| Physical worker | 10 (7) | 4 (7) | 4 (8) | 3 (6) | ||
| Pregabalin or Gabapentin | 84 (57) | 39 (72) | 0.052 | 27 (56) | 34 (71) | 0.138 |
| Opioids | 65 (44) | 34 (63) | 0.018 | 24 (50) | 29 (60) | 0.305 |
| Smoking within 2 h of bedtime | 24 (16) | 7 (13) | 0.558 | 8 (17) | 7 (15) | 0.779 |
| Alcohol within 2 h of bedtime | 19 (13) | 6 (11) | 0.730 | 5 (10) | 6 (12) | 0.749 |
| Coffee | 15 (10) | 4 (7) | 0.786 | 4 (8) | 4 (8) | 1.000 |
| Tea | 20 (14) | 6 (11) | 0.640 | 8 (17) | 4 (8) | 0.217 |
| Lower extremities | 35 (24) | 12 (22) | 0.814 | 12 (25) | 11 (23) | 0.811 |
| Upper extremities | 22 (15) | 9 (17) | 0.767 | 8 (17) | 9 (19) | 0.789 |
| Global score | 12.1 ± 3.3 | 12.6 ± 3.6 | 0.365 | 12.5 ± 3.1 | 12.3 ± 3.2 | 0.748 |
| Sleep quality | 1.9 ± 0.9 | 1.9 ± 1.1 | 0.836 | 2.1 ± 0.8 | 1.9 ± 1.1 | 0.340 |
| Sleep latency | 3.2 ± 2.1 | 3.9 ± 2.2 | 0.027 | 3.3 ± 2.1 | 4.0 ± 2.1 | 0.111 |
| Sleep duration | 2.1 ± 1.0 | 2.1 ± 1.0 | 0.809 | 2.2 ± 1.0 | 2.0 ± 1.0 | 0.543 |
| Sleep efficiency | 1.4 ± 0.7 | 1.2 ± 0.6 | 0.019 | 1.5 ± 0.7 | 1.1 ± 0.5 | 0.001 |
| Sleep disturbance | 1.7 ± 0.6 | 1.7 ± 0.7 | 0.883 | 1.8 ± 0.6 | 1.7 ± 0.7 | 0.442 |
| Use of sleep medication | 0.4 ± 0.7 | 0.4 ± 0.7 | 0.702 | 0.3 ± 0.6 | 0.3 ± 0.7 | 0.874 |
| Daytime dysfunction | 1.3 ± 0.9 | 1.4 ± 1.0 | 0.655 | 1.4 ± 1.0 | 1.4 ± 1.0 | 0.833 |
Data were presented by number (%) of patients or mean ± standard deviation.
Comparison of initial radiologic profile.
| Unmatched cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
| Conservative group | Surgical group | p-value | Conservative group | Surgical group | p-value | |
| Dural sac cross-sectional area (mm2) at the most severe level | 57 ± 34 | 45 ± 30 | 0.014 | 51 ± 29 | 45 ± 32 | 0.323 |
| Morphologic grade of stenosis at the most severe level | ||||||
| A or B | 37 (25) | 8 (15) | 0.147 | 10 (21) | 7 (15) | 0.530 |
| C | 66 (45) | 23 (43) | 21 (44) | 19 (40) | ||
| D | 44 (30) | 23 (43) | 17 (35) | 22 (46) | ||
| Grade 0 or 1 | 28 (19) | 7 (13) | 0.300 | 10 (21) | 7 (15) | 0.250 |
| Grade 2 | 60 (41) | 19 (35) | 22 (46) | 17 (35) | ||
| Grade 3 | 59 (40) | 28 (52) | 16 (33) | 24 (50) | ||
Data were presented by number (%) of patients or mean ± standard deviation.
Comparison of prescribed medications during the follow-up period.
| Conservative group | Surgical group | p-value | |
|---|---|---|---|
| During previous 4 weeks | 46 (96) | 44 (92) | 0.399 |
| At 6-week follow-up | 45 (94) | 40 (83) | 0.109 |
| At 3-month follow-up | 42 (88) | 7 (15) | < 0.001 |
| At 6-month follow-up | 44 (92) | 2 (4) | < 0.001 |
| During previous 4 weeks | 24 (50) | 29 (60) | 0.305 |
| At 6-week follow-up | 34 (71) | 23 (48) | 0.022 |
| At 3-month follow-up | 27 (56) | 3 (6) | < 0.001 |
| At 6-month follow-up | 19 (38) | 1 (2) | < 0.001 |
| During previous 4 weeks | 27 (56) | 34 (71) | 0.138 |
| At 6-week follow-up | 28 (58) | 15 (31) | 0.008 |
| At 3-month follow-up | 26 (54) | 4 (8) | < 0.001 |
| At 6-month follow-up | 24 (50) | 2 (4) | < 0.001 |
| During previous 4 weeks | 12 (25) | 11 (23) | 0.811 |
| Type of sleep medication | 0.307 | ||
| Hypnotics | 8 | 5 | |
| Benzodiazepine | 3 | 4 | |
| Anti-depressant | 1 | 2 | |
| At 6-week follow-up | 12 (25) | 11 (23) | 0.811 |
| At 3-month follow-up | 13 (27) | 11 (23) | 0.637 |
| At 6-month follow-up | 14 (29) | 10 (21) | 0.346 |
Data were presented by number (%) of patients or mean ± standard deviation.
Comparison of changes in clinical profile within the matched cohorts.
| Conservative group | Surgical group | p-value | |
|---|---|---|---|
| Initial | 40.1 ± 16.5 | 41.0 ± 17.7 | 0.810 |
| At 6-week follow-up | 25.9 ± 15.3 | 25.7 ± 14.4 | 0.949 |
| At 3-month follow-up | 23.4 ± 13.5 | 13.4 ± 6.4 | < 0.001 |
| At 6-month follow-up | 19.1 ± 12.8 | 12.1 ± 7.9 | 0.002 |
| Global score | |||
| Initial | 12.5 ± 3.1 | 12.3 ± 3.2 | 0.748 |
| At 6-week follow-up | 9.0 ± 3.2 | 6.7 ± 2.9 | < 0.001 |
| At 3-month follow-up | 9.8 ± 3.1 | 6.6 ± 2.9 | < 0.001 |
| At 6-month follow-up | 9.3 ± 4.0 | 5.8 ± 2.6 | < 0.001 |
| Initial | – | – | |
| At 6-week follow-up | 29 (60) | 37 (77) | 0.078 |
| At 3-month follow-up | 22 (46) | 39 (81) | < 0.001 |
| At 6-month follow-up | 24 (50) | 41 (85) | < 0.001 |
| Sleep quality | |||
| Initial | 2.1 ± 0.8 | 1.9 ± 1.1 | 0.340 |
| At 6-week follow-up | 0.9 ± 0.9 | 0.7 ± 0.5 | 0.348 |
| At 3-month follow-up | 1.1 ± 0.8 | 0.9 ± 0.7 | 0.111 |
| At 6-month follow-up | 1.0 ± 1.0 | 0.6 ± 0.6 | 0.021 |
| Sleep latency (minutes) | |||
| Initial | 3.3 ± 2.1 (46 ± 25) | 4.0 ± 2.1 (52 ± 26) | 0.032 |
| At 6-week follow-up | 2.6 ± 2.0 (38 ± 19) | 1.8 ± 1.7 (30 ± 16) | 0.111 |
| At 3-month follow-up | 2.9 ± 2.2 (40 ± 22) | 1.4 ± 1.0 (25 ± 17) | 0.001 |
| At 6-month follow-up | 2.6 ± 2.0 (37 ± 23) | 1.3 ± 1.5 (24 ± 15) | 0.001 |
| Sleep duration (minutes) | |||
| Initial | 2.2 ± 1.0 (323 ± 63) | 2.0 ± 1.0 (326 ± 61) | 0.543 |
| At 6-week follow-up | 1.9 ± 1.0 (343 ± 63) | 1.6 ± 1.0 (364 ± 60) | 0.230 |
| At 3-month follow-up | 1.8 ± 1.0 (338 ± 72) | 1.4 ± 1.0 (375 ± 68) | 0.059 |
| At 6-month follow-up | 1.7 ± 1.1 (343 ± 78) | 1.1 ± 1.0 (373 ± 70) | 0.152 |
| Sleep efficiency | |||
| Initial | 1.5 ± 0.7 | 1.1 ± 0.5 | 0.001 |
| At 6-week follow-up | 1.2 ± 0.9 | 0.9 ± 1.0 | 0.146 |
| At 3-month follow-up | 1.4 ± 1.0 | 1.0 ± 0.9 | 0.029 |
| At 6-month follow-up | 1.4 ± 1.1 | 1.1 ± 1.0 | 0.184 |
| Sleep disturbance | |||
| Initial | 1.8 ± 0.6 | 1.7 ± 0.7 | 0.442 |
| At 6-week follow-up | 1.1 ± 0.8 | 0.7 ± 0.6 | 0.011 |
| At 3-month follow-up | 1.1 ± 0.8 | 0.8 ± 0.6 | 0.048 |
| At 6-month follow-up | 1.1 ± 1.0 | 0.5 ± 0.7 | < 0.001 |
| Use of sleep medication | |||
| Initial | 0.3 ± 0.6 | 0.3 ± 0.7 | 0.874 |
| At 6-week follow-up | 0.3 ± 0.6 | 0.2 ± 0.4 | 0.345 |
| At 3-month follow-up | 0.3 ± 0.6 | 0.3 ± 0.5 | 0.454 |
| At 6-month follow-up | 0.4 ± 0.6 | 0.2 ± 0.5 | 0.260 |
| Daytime dysfunction | |||
| Initial | 1.4 ± 1.0 | 1.4 ± 1.0 | 0.833 |
| At 6-week follow-up | 1.1 ± 0.8 | 0.8 ± 0.7 | 0.051 |
| At 3-month follow-up | 1.0 ± 0.8 | 0.7 ± 0.8 | 0.030 |
| At 6-month follow-up | 1.2 ± 0.9 | 0.7 ± 0.7 | 0.012 |
Data were presented by number (%) of patients or mean ± standard deviation.
Figure 2Comparison of changes in clinical profile within the matched cohorts (*significant intergroup difference of p < 0.05). (a) Comparison of Oswestry Disability Index (ODI) score. (b) Comparison of Pittsburgh sleep quality index (PSQI) score. Middle line in the box: median value; x mark within the box: mean value; upper and lower edges of box: interquartile range including 50% of the observations; dots outside box: outliers. Whisker lines extend for 1.5 times the interquartile range.
Figure 3Changes in global PSQI score and scores of its seven subcategories between the three time points (at 6 weeks, 3 months, and 6 months) and their initial values. (a) Global Pittsburgh sleep quality index (PSQI) score. (b) Sleep quality index. (c) Sleep latency index. (d) Sleep duration index. (e) Sleep efficacy index. (f) Sleep disturbance index. (g) Sleep medication index. (h) Daytime dysfunction index. (*significant intergroup difference of p < 0.05; #significant intergroup difference of p < 0.01).
Figure 4Comparison of sleep latency and total sleep time assessed by actual minutes (*significant intergroup difference of p < 0.05). (a) Comparison of sleep latency assessed by minutes. (b) Comparison of total sleep time assessed by minutes.
Effect of surgical treatment on the improvement of PSQI score at 6-month follow-up: multivariate analysis.
| Cohort | Model | Group | Odds ratios | 95% confidence interval | p-value |
|---|---|---|---|---|---|
| Matched cohort | Model 1 | Conservative group | – | – | – |
| Surgical group | 8.589 | (2.755, 26.772) | < 0.001 | ||
| Model 2 | Conservative group | – | – | – | |
| Surgical group | 8.810 | (2.705, 28.690) | < 0.001 | ||
| Whole cohort | Model 1 | Conservative group | – | – | – |
| Surgical group | 8.802 | (3.505, 22.104) | < 0.001 | ||
| Model 2 | Conservative group | – | – | – | |
| Surgical group | 8.264 | (3.267, 20.907) | < 0.001 |
Model 1: adjusted for age, sex, Charlson comorbidity index score, Hamilton depression rating scale, initial Oswestry disability index score, and initial global PSQI score.
Model 2: adjusted for age, sex, Charlson comorbidity index score, Hamilton depression rating scale, initial Oswestry disability index score, initial global PSQI score, dural sac cross-sectional area, central-type stenosis by Shizas et al., and foraminal-type stenosis by Lee et al.
Data were presented by number (%) of patients.
Factors associated with failure in sleep improvement: subgroup analysis within the whole conservative cohort.
| Whole conservative group | |||
|---|---|---|---|
| Increase in PSQI ≥ 3 | Increase in PSQI < 3 | p-value | |
| Number of patients | 67 | 80 | |
| Age | 70.2 ± 10.1 | 69.0 ± 10.8 | 0.948 |
| Sex (male:female) | 28:39 (1:1.4) | 33:47 (1:1.4) | 0.947 |
| BMI (kg/m2) | 24.0 ± 3.1 | 24.8 ± 3.1 | 0.123 |
| Charlson comorbidity index score | 1.6 ± 1.4 | 1.2 ± 1.3 | 0.095 |
| Hamilton depression rating scale | 11.0 ± 7.6 | 14.2 ± 9.2 | 0.022 |
| Oswestry disability index score | 36.4 ± 17.8 | 40.2 ± 17.5 | 0.197 |
| Back pain | 4.8 ± 1.4 | 4.9 ± 1.3 | 0.903 |
| Leg pain | 4.9 ± 1.6 | 5.3 ± 1.6 | 0.105 |
| Dural sac cross-sectional area (mm2) at the most severe level | 53 ± 30 | 60 ± 36 | 0.179 |
| Morphologic grade of stenosis at the most severe level | |||
| A or B | 16 (24) | 21 (26) | 0.779 |
| C | 29 (43) | 37 (46) | |
| D | 22 (33) | 22 (28) | |
| Grade 0 or 1 | 12 (18) | 16 (20) | 0.026 |
| Grade 2 | 35 (52) | 25 (31) | |
| Grade 3 | 20 (30) | 39 (49) | |
Data were presented by number (%) of patients or mean ± standard deviation.
Correlation between changes in pain and disability scale and changes in global PSQI score within the whole cohort.
| All | Conservative group | Surgical group | ||||
|---|---|---|---|---|---|---|
| Correlation coefficient | p-value | Correlation coefficient | p-value | Correlation coefficient | p-value | |
| Back pain | 0.360 | < 0.001 | 0.171 | 0.038 | 0.343 | 0.011 |
| Leg pain | 0.555 | < 0.001 | 0.297 | < 0.001 | 0.681 | < 0.001 |
| Changes in Oswestry disability index score | 0.175 | 0.013 | 0.223 | 0.007 | 0.207 | 0.133 |